Equine melanoma update puts H-FIRE in the clinical spotlight
Bottom line
EquiManagement’s September 17, 2026, Disease Du Jour podcast spotlights equine melanoma and a newer treatment approach called high-frequency irreversible electroporation, or H-FIRE, in a conversation with Virginia Tech equine surgeon Elsa Ludwig, DVM, PhD, MS, CVA, DACVS-LA. Ludwig said melanomas make up roughly 6% to 15% of equine skin tumors and affect up to 80% of older gray horses, with common tumor sites under the tail, around the perineum, and on the external genitalia. The broader context is that H-FIRE is moving from investigational work into limited clinical availability: Virginia Tech’s Marion duPont Scott Equine Medical Center says it now offers H-FIRE as a skin tumor treatment option for horses and describes it as one of only two U.S. sites currently providing the modality. (equimanagement.com)
Why it matters: For equine and mixed-animal veterinarians, the update is less about a single podcast episode and more about a shift in how melanoma may be managed in select cases. Older guidance often leaned toward monitoring small lesions, but more recent expert commentary has argued for earlier intervention because equine melanoma is progressive and can become more invasive over time. H-FIRE is drawing interest because it is designed as a non-thermal ablation method that can often be performed in standing, sedated horses, potentially expanding options for pet parents whose horses have tumors in anatomically challenging areas or have failed prior local therapies. Published veterinary reports from Virginia Tech have described use of H-FIRE-style pulsed electrical field treatment in awake standing horses with superficial tumors, and a newer Frontiers study evaluated integrated-time nanosecond pulse irreversible electroporation in spontaneous equine melanoma. (equimanagement.com)
What to watch: Watch for larger clinical datasets, recurrence outcomes, and whether H-FIRE expands beyond a small number of referral centers into broader equine oncology practice. (emc.vetmed.vt.edu)
Key facts
- Episode date
- September 17, 2026
- Topic
- Equine melanoma and H-FIRE
- Expert quoted
- Elsa Ludwig, DVM, PhD, MS, CVA, DACVS-LA
- Melanoma share of equine skin tumors
- About 6% to 15%
- Horses affected
- Up to 80% of older gray horses
- Common tumor sites
- Under the tail, around the perineum, and on the external genitalia
- Treatment status
- Virginia Tech now offers H-FIRE clinically for horses
- U.S. availability
- One of only two U.S. sites currently providing H-FIRE for horses
EquiManagement’s latest Disease Du Jour episode, published September 17, 2026, puts a spotlight on equine melanoma and on H-FIRE, a pulsed electrical field technology that Virginia Tech surgeon Elsa Ludwig says she is using to treat skin tumors in horses. The episode lands as H-FIRE appears to be moving from research-heavy discussion into real-world referral practice, with Virginia Tech now advertising the service through its Marion duPont Scott Equine Medical Center. (equimanagement.com)
That timing matters because equine melanoma has long sat in an uncomfortable gray zone between “watch it” and “treat it now.” EquiManagement’s earlier melanoma coverage highlighted a change in thinking from older advice that small melanomas should be left alone. In that 2020 report, Derek Knottenbelt urged practitioners to intervene earlier, arguing that melanoma is progressive, becomes harder to manage with time, and may disseminate internally after beginning as a skin lesion. (equimanagement.com)
In the new podcast coverage, Ludwig said melanomas account for about 6% to 15% of equine skin tumors and affect up to 80% of older gray horses. Common locations include the ventral tail, perineal region, and external genitalia, all sites that can make conventional surgery difficult depending on size, depth, and local contamination risks. That helps explain interest in H-FIRE and related electroporation platforms as local-control tools rather than simple excision substitutes. (equimanagement.com)
The research base is still early, but it is growing. A 2019 Frontiers in Veterinary Science report from Virginia Tech described treatment of superficial tumors in five awake standing horses using H-FIRE, including melanoma cases, and noted the appeal of avoiding the muscle contractions associated with conventional irreversible electroporation. A more recent Frontiers study investigated integrated-time nanosecond pulse irreversible electroporation against spontaneous equine melanoma, reflecting continued refinement of electroporation-based tumor ablation in this species. Virginia Tech’s clinical materials now say H-FIRE can be used for sarcoids, melanomas, squamous cell carcinomas, and some rarer skin tumors, and that most horses can be treated standing and sedated with local anesthesia. (pmc.ncbi.nlm.nih.gov)
Industry reaction is still limited, and there does not yet appear to be broad multi-center commentary on H-FIRE in horses. But the way referral centers are framing it is telling. Virginia Tech describes H-FIRE as a non-thermal tumor ablation option now available clinically and says it is one of only two U.S. locations offering the treatment for horses. That suggests the technology remains specialized, referral-based, and likely best suited for carefully selected cases rather than routine first-line use in general practice. That last point is an inference based on the limited number of access points and the still-small published evidence base. (emc.vetmed.vt.edu)
Why it matters: For veterinary professionals, especially equine practitioners and oncologic referral teams, H-FIRE represents a potentially useful addition in a disease category where case selection is everything. Melanomas in gray horses are common, lesion behavior is variable, and tumor location often drives the practical treatment decision as much as biology does. A modality that can be delivered in standing horses and may spare surrounding tissue could be valuable for tumors in the tailhead or perineal region, for horses that are poor anesthetic candidates, or for pet parents weighing quality-of-life concerns against repeated surgery. At the same time, clinicians will still need to counsel carefully around cost, availability, repeat-treatment needs, and the fact that published outcomes remain relatively limited. (equimanagement.com)
The bigger clinical takeaway may be that melanoma management in horses continues to move toward earlier, more proactive intervention, while the menu of local therapies gets more sophisticated. H-FIRE is part of that trend, but not the whole story. Existing options such as excision, intralesional chemotherapy, and, in some settings, off-label immunotherapy still matter, and referral conversations will likely center on matching lesion type, location, and progression risk to the least disruptive effective option. (equimanagement.com)
What to watch: The next milestones are better outcome reporting, including recurrence and durability data, broader publication of case-selection criteria, and any sign that additional referral hospitals adopt H-FIRE beyond the handful of centers offering it today. (emc.vetmed.vt.edu)